50.7K
Downloads
78
Episodes
AllergyTalk is a round-up of the latest in the field of allergy and immunology by the American College of Allergy, Asthma & Immunology. In each bi-monthly episode, hosts Gerald Lee, MD and Stanley Fineman, MD invite a guest to discuss key articles reviewed in the current issue of AllergyWatch.
Episodes
Wednesday Jul 03, 2024
Wednesday Jul 03, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we are joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk .
To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch .
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
The impact of prenatal dog keeping on infant gut microbiota development.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Rathkopf have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Wednesday Jun 26, 2024
Wednesday Jun 26, 2024
Today we joined by Dr. Samanta Knox, MD from Gunderson Health System in La Crosse, WI where we review the Jan-Feb 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk
To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Knox have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Wednesday Jun 26, 2024
Wednesday Jun 26, 2024
Today we joined by Dr. Samanta Knox, MD from Gunderson Health System in La Crosse, WI where we review the Jan-Feb 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can earn CME credit by listening to this podcast! For information about CME credit, go to https://education.acaai.org/allergytalk.
To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch.
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Race and ethnicity define disparate clinical outcomes in chronic rhinosinusitis.
Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study.
Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Knox have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Thursday Jun 20, 2024
Thursday Jun 20, 2024
Originally Recorded 4/18/2023
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
In Kids With Allergic Rhinitis, Remember To Address Sleep Problems!
Azithromycin as an Option for Poorly Controlled Childhood Asthma
Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.
Data Suggest ‘Real-World Benefit’ of Early Introduction
Changes in Australian food anaphylaxis admission rates following introduction of updated allergy prevention guidelines.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Joshi has the following disclosures:
- Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
- Clinical trial funding: GlaxoSmithKline Sanofi
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Thursday Jun 20, 2024
Thursday Jun 20, 2024
Originally Recorded 4/18/2023
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Combined ICS/SBA Reduces Asthma Exacerbations
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
CRSwNP Patients have Impaired Sense of Smell and Taste
Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.
Anti-dsDNA IgG May Predict Nasal Polyp Recurrence
Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Joshi has the following disclosures:
- Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
- Clinical trial funding: GlaxoSmithKline Sanofi
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Tuesday Jun 11, 2024
Tuesday Jun 11, 2024
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Vivan Hernandez-Trujillo, MD from Nicklaus Children’s Hospital in Miami, Florida where we review the July-Aug 2022 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Safety of Live Attenuated Influenza Vaccine in Children With Asthma.
Obesity alters pathology and treatment response in inflammatory disease.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose
Dr. Hernandez-Trujillo:
Speaker Takeda, CSL
Advisory boards Takeda, Regeneron, Sanofi
Consultant Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network
Dr. Fineman:
Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Tuesday Jun 04, 2024
Tuesday Jun 04, 2024
Originally recorded 11/24/21
For today’s episode we will be reviewing three articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Is Alpha-Gal Really a Problem in Patients with Food Allergy?
Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018.
Family history alone isn’t a Risk Factor for Peanut Allergy
Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy.
Peripheral eosinophil counts: a moving target
Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Saturday Mar 02, 2024
Saturday Mar 02, 2024
Welcome to a special 2 part episode of Allergytalk!
On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In second part of a 2 part series, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382
Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Chinthrajah has consulted for Genentech and Novartis.
Dr. Vickery has consulted for Genentech and Novartis
Saturday Mar 02, 2024
Saturday Mar 02, 2024
Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a 2 part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Children and Adults (OUtMATCH) study that led to this FDA indication. In Part II, we will discuss important considerations in implementing omalizumab for food allergy in your practice.
Speakers:
Dr. Robert Wood, MD, the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and Division Director at Johns Hopkins University School of Medicine and Primary Investigator of the OUtMATCH study.
Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.
Important Links:
Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, YovetichN, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382
Updated FDA label for omalizumab:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has nothing to disclose.
Dr. Wood has consulted for Genentech.
Dr. Vickery has consulted for Genentech and Novartis
Thursday Dec 21, 2023
Thursday Dec 21, 2023
For this episode we will be reviewing three articles from the Nov-Dec 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
Articles Reviewed:
Tezepelumab Reduces Exacerbations – Even at Lower Eosinophil Counts
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Predicting Response to Aspirin Therapy in NSAID-ERD
Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.
Can Technology Aid in Asthma Therapy Adherence?
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
At the time of recording, the speakers had the following disclosures:
Dr. Lee has nothing to disclose
Dr. Kalangara Speaker and Consultant: GlaxoSmithKline
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst